JamesAlanSimonMD

Obstetrics & Gynecology • Washington, DC

General Gynecology, Reproductive Endocrinology & Infertility

Clinical Professor of Obstetrics & Gynecology, Geo Wash University

Join to view full profile

Dr. Simon is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Simon's full profile

Already have an account?

Office
1850 M St NW
Ste 450
Washington, DC 20036
Phone+1 202-293-1000

Fax+1 202-463-6150

Education & Training

UCLA David Geffen School of Medicine/UCLA Medical CenterFellowship, Reproductive Endocrinology and Infertility, 1984
George Washington UniversityResidency, Obstetrics and Gynecology, 1978 - 1982
Rush Medical College of Rush University Medical CenterClass of 1978

Certifications & Licensure

CA State Medical License 1982 - Present
OH State Medical License 2024 - 2026
CO State Medical License 2024 - 2025
TN State Medical License 2024 - 2025
DC State Medical License 1979 - 2024
VA State Medical License 1979 - 2024
MD State Medical License 1979 - 2009
American Board of Obstetrics and Gynecology Obstetrics & Gynecology
American Board of Obstetrics and Gynecology Reproductive Endocrinology/Infertility
American Association of Sex Educators, Counselors and TherapistsCertified Sexuality Counselor
International Society for Clinical DensitometryCertified Clinical Densitometrist
International Society for the Study of Women's Sexual HealthISSWSH Fellow
North American Menopause SocietyNAMS Certified Menopause Practitioner

Awards, Honors, & Recognition

Top Washington Physician
Best Doctors In America
America’s Top Obstetricians and Gynecologists
Super Doctor SuperDoctors.com
Join now to see all

Clinical Trials

Efficacy/Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms (VMS) Start of enrollment: 2011 May 01
Completed
Phase 3
Study to Evaluate the Safety and Bioequivalence of Estradiol Vaginal Inserts, 10 mcg and Vagifem® 10 mcg and Compare to Placebo Start of enrollment: 2012 Mar 01
Completed
Phase 3
Efficacy and Safety of Elagolix in Combination With Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women Start of enrollment: 2015 Dec 22
Completed
Phase 3
An Extension Study to Evaluate the Efficacy and Safety of Elagolix in Premenopausal Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids Start of enrollment: 2016 Sep 14
Completed
Phase 3
Assess Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids Start of enrollment: 2017 Jun 30
Active, not recruiting
Phase 3
A Clinical Study to Evaluate the Safety and Efficacy of Elagolix in Participants With Moderate to Severe Endometriosis-Associated Pain Start of enrollment: 2017 Jul 07
Completed
Phase 3
Long-Term Safety Study of Elagolix in Combination With Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women Start of enrollment: 2017 Jan 04
Active, not recruiting
Phase 3
Assess Safety and Efficacy of Vilaprisan in Subjects With Endometriosis Start of enrollment: 2018 Jul 04
Terminated
Phase 2
Dysport in Vulvodynia Phase II Study Start of enrollment: 2018 Jun 11
Terminated
Phase 2
Study of the Safety and Efficacy of MR-100A-01 in Approximately 1200 Healthy Women for up to 13 Cycles Start of enrollment: 2021 Oct 26
Active, not recruiting
Phase 3
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

94 citations
Low-dose paroxetine 7.5 mg for menopausal vasomotor symptoms: two randomized controlled trials.
James A. Simon, David Portman, Hana Mekonnen, Kazem Kazempour, Sailaja Bhaskar
Menopause. 2013-10-01
162 citations
Ospemifene, a novel selective estrogen receptor modulator for treating dyspareunia associated with postmenopausal vulvar and vaginal atrophy.
David Portman, Gloria Bachmann, James A. Simon
Menopause. 2013-06-01
116 citations
Hypoactive Sexual Desire Disorder: International Society for the Study of Women's Sexual Health (ISSWSH) Expert Consensus Panel Review
Irwin Goldstein, Noel N. Kim, Anita H. Clayton, Leonard R. Derogatis, Annamaria Giraldi
Mayo Clinic Proceedings. 2017-01-01

Press Mentions

Long-Term Data Support Non-Hormonal Drug for Hot-Flash ManagementSeptember 15th, 2024
Data from Phase III Study OASIS 3 Support Efficacy and Long-Term Safety of Investigational Compound Elinzanetant in the Treatment of Moderate to Severe Vasomotor Symptoms Associated with MenopauseSeptember 10th, 2024
Elinzanetant Reduces Menopausal SymptomsAugust 23rd, 2024
Join now to see all